---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-24-000004"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:59:13.785433+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biogen Q4 revenue $2.4B, GAAP EPS $1.71; 2024 Non-GAAP EPS guidance $15-$16

## Summary
- Q4 2023 revenue $2.4B (-6% YoY); GAAP EPS $1.71 vs $3.79; Non-GAAP EPS $2.95 vs $4.05
- Full year 2023 revenue $9.8B (-3% YoY); GAAP EPS $7.97 vs $20.87; Non-GAAP EPS $14.72 vs $17.67
- EPS negatively impacted by $0.35 from ADUHELM closeout costs; LEQEMBI co-promotion announced
- 2024 guidance: Non-GAAP EPS $15.00-$16.00 (~5% growth vs 2023); revenue expected down low- to mid-single digit
- SKYCLARYS launched with ~1,000 patients; ZURZUVAE postpartum depression launch; 'Fit for Growth' $1B gross savings by 2025

## SEC filing metadata
- accession: 0000875045-24-000004
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/biib-20240213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-24-000004
- JSON: https://secwatch.observer/filing/0000875045-24-000004.json
- Plain text: https://secwatch.observer/filing/0000875045-24-000004.txt

## Key facts
- Earnings Releases
  BIOGEN INC. reported fourth quarter 2023 results: revenue $2.4 billion, EPS GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95.
  - Period: fourth quarter 2023
  - Revenue: $2.4 billion
  - EPS: GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95
  - Result: reported results
  source text: Fourth quarter 2023 revenue $2.4 billion; GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm
- Earnings Releases
  BIOGEN INC. reported full year 2024 results: revenue total revenue to decline by a low- to mid-single digit percentage vs. 2023, EPS Non-GAAP EPS of $15.00 to $16.00. Guidance initiated.
  - Period: full year 2024
  - Revenue: total revenue to decline by a low- to mid-single digit percentage vs. 2023
  - EPS: Non-GAAP EPS of $15.00 to $16.00
  - Guidance: initiated
  - Result: guidance update
  source text: Full year 2024 financial guidance: Non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point • Expect total revenue to decline by a low- to mid-single digit percentage vs. 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm
- Earnings Releases
  BIOGEN INC. reported full year 2023 results: revenue $9.8 billion, EPS GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72.
  - Period: full year 2023
  - Revenue: $9.8 billion
  - EPS: GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72
  - Result: reported results
  source text: Full year 2023 revenue $9.8 billion; GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.